Welcome to our dedicated page for Tharimmune news (Ticker: THAR), a resource for investors and traders seeking the latest updates and insights on Tharimmune stock.
Tharimmune, Inc., trading under the symbol THAR on NASDAQ, is a clinical-stage biotechnology company dedicated to developing therapeutic solutions for rare immune, inflammatory, and oncologic diseases. The company's primary focus is the advancement of its portfolio of therapeutic candidates, with a notable asset, TH104, aimed at treating chronic, debilitating pruritus in primary biliary cholangitis (PBC), a rare and orphan liver disease with no known cure.
Tharimmune is actively engaged in the development of novel multi-specific antibodies targeting unique epitopes in multiple solid tumors. These antibodies employ new mechanisms of action against validated targets, offering innovative solutions in the field of immuno-oncology. A key collaboration with OmniAb, Inc. allows Tharimmune to leverage advanced antibody discovery technology for these specified targets.
The company recently announced the pricing of an underwritten public offering, raising $10 million to fund its ongoing phase 2 trial for TH104, expected in 2024, and other general corporate purposes. This financial boost will support their clinical and non-clinical programs, ensuring sustained progress towards their mission.
In its latest Phase 1 trial conducted in India, TH104 demonstrated a significant reduction in pruritus among patients with chronic liver disease, with a 33.3% decrease in 24-hour mean itching intensity score. The trial also confirmed the safety of TH104, showing no unexpected treatment-emergent adverse events. These promising results lay the groundwork for an upcoming Phase 2a trial in the US, anticipated to yield pivotal data in 2024.
Tharimmune has consistently demonstrated a commitment to scientific excellence and patient care. Their ongoing research is poised to make significant contributions to the treatment of liver-related and other pruritogenic inflammatory conditions, as well as novel therapies for cancer treatment. With a strong pipeline and strategic partnerships, Tharimmune is well-positioned to lead advancements in biotechnology.
Tharimmune, Inc. (NASDAQ:THAR) will participate in two investor conferences in May. Randy Milby, CEO, will present at the Planet MicroCap Showcase: VEGAS 2024 and attend the EF Hutton Annual Global Conference. Investors can register online to meet with the company.
FAQ
What is the current stock price of Tharimmune (THAR)?
What is the market cap of Tharimmune (THAR)?
What is Tharimmune, Inc.'s primary focus?
What is TH104?
How did Tharimmune perform in its recent Phase 1 trial for TH104?
What are Tharimmune's plans for TH104 moving forward?
How much did Tharimmune raise in its recent public offering?
What partnerships does Tharimmune have?
What are the primary results from the Phase 1 trial of TH104?
What other projects are Tharimmune working on?
How is Tharimmune funded for its upcoming projects?
What can we expect from Tharimmune in the near future?
